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1.INTRODUCTION 
Like most industrialized countries, the European Community ha~ a variety of 
health and environmental protection laws that could be applied to 
biotechnological processes and products. For instance, Community legislation 
covers risks relating to food additives, pharmaceuticals, feedstuffs, 
cosmetics, and industrial chemicals. But these Community laws are usually 
limited by their application to commercial products only. They were not 
designed to monitor accidental release or the deliberate use of exotic or 
genetically modified organisms. 
Other Community laws cover health and environmental risks to workers and 
the public from industrial processes or wastes. These laws are similarly 
limited by their application to chemicals; they, too, were not designed to 
anticipate, evaluate and control risks from genetically modified organisms. 
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1.A. THE NATURE OF RISKS FROM MODERN BIOTECHNOLOGY 
• 
In the past fifteen yeaPs, new developments in techniques to pecombine in 
vitro the DNA from different organisms, permit precise alteration, 
construction, recombination, deletion and translocation of genes to obtain a 
desired phenotype. These procedures are relatively simple to learn and 
apply. Consequently, they are potentially accessible to a wide range of 
industrial, agricultural and other organisations, large and small. Although 
the costs of research and development may in some areas have been enormous, 
in other areas the entry cost is negligible, the benefits enticing. It is 
therefore unsurprising that many hundreds of companies are already active in 
this field and commercialization of their products is progressing much more 
rapidly than was foreseen a few years ago. 
Thus, although biotechnology is as old as human civilization, the scale of 
international trade and this rapidly accelerating industrial progress means 
that the application of these new techniques of genetic manipulation will 
increase the potential scale of their impacts by several orders of magnitude. 
The "quality" of hazard posed by a particular application of biotechnology 
may be the same at all stages of development from research to large-scale 
production and use. However, the overall risks <intrinsic hazard + exposure 
to the hazard> could increase substantially with the scale of production and 
use. 
In the case of fermentation technologies, the genetically modified 
microorganism is usually contained during the research or manufacturing 
process, and it is usually destroyed when its work has been accomplished. At 
this stage the risks would arise from accidental release of the microcrganism 
and exposure of workers inside the plant, or people and the environment 
outside the plant. Further risks might arise from the generation of wastes. 
In the case of genetically modified or exotic microorganisms intended for 
use in the environment, three categories of direct risks are involved: 
1) Ecological disruption <for example, due to a lack of natural 
enemies>; 
2) Infectivity, pathogenicity or toxicity to nontarget organisms 
<plants, animals, humans>; and 
3 > Exchange of genetic material with other organisms or disruption of 
ecosystems and consequent risks of <1> and <2>. 
1.B. THE EUROPEAN COMMISSION'S APPROACH TO BIOTECHNOLOGY REGULATION 
The European Commission's interest in controlling the potential rlsKs from 
biotechnology is obvious. Long experience in such fields as health care and 
environmental protection demonstrates that it is better to identify and 
evaluate potential risks as far as possible in advance of large-scale 
production, so that the appropriate measures to limit and control these risks 
can be taken. Such risk assessments should be followed up by·monitoring and 
re-evaluation in the light of growing experience. 
Clearly, as in the case of chemical-based industrial processes and products 
in the past, the onus must be laid upon the innovator or producer to carry 
out the initial risk assessment and to provide the regulatory authorities 
with data adequate for a risk assessment and monitoring. 
Several important arguments underly the European Commission's commitment to 
providing adequate regulation of biotechnology: 
1 > The health and environmental impacts of biotechnology might easily 
cross national frontiers - national regulations cannot protect against 
risks from genetically modifed organisms; 
2> EC regulation wou1a offer the scale of the common market for 
biotechnological products, and thereby provide a more economically 
attractive environment for European industrial innovation in 
biotechnology; 
3> Pooling the data relevant to the regulatory assessment of risks from 
biotechnological innovations at the European level would mean a more 
rapid accumulation of experience and hence the more timely and 
appropriate development and adaptation of regulations in the light of 
experience; 
-4 > European Community regulation would mean a more efficient use of 
resources, both in the underlying research, and in the development and 
application of regulations. 
\' 
The probability of such a risk occurring depends upon five factors 
1) The possibility of release into the environment; 
• 
2) The possibility that the organism will survive there; 
3) The possibility that the organism will reproduce and multiply; 
4) The possibility that the organism will make contact with a 
receptive environment <gene exchange, dissemination>; 
5> The possibility that the organism will be harmful. 
Hence, the direct risks from a particular genetically modified organism are 
probably small, but, nevertheless, the consequences could be very large. They 
might give rise to problems comparable with those created in the past by 
incursions of natural pathogens into novel environments <for example, 
measles, typhoid, smallpox in North America, Dutch elm disease>. 
Indirect risks from modern, large-scale uses of genetically modified 
organisms also must be considered, such as the potential loss of native plant 
and animal species posed by large-scale industrialized agricultural 
practices. Such risks, however, may derive more from the scale of 
applications than the intrinsic harmfulness of the biotechnological product. 
A useful point of common international refel~ence on these issues will be 
provided by the publication later in 1986 of a report by an ad hoc group of 
experts, convened by the OECD. This report will be entitled: 
"Recombinant DNA Safety Considerations: Safety Considerations for Industrial, 
Agricultural and Environmental Applications of Organisms Derived by 
Recombinant DNA Techniques". 
The summary and recommendations are attached as an annex to this report. 
Experts from most Community Member States and from the Commission were among 
those who approved unanimously the text at their final working meeting 
,<Paris, 2-6 December, 1985). 
.. 
1.C. THE PURPOSE OF THIS PAPER 
At this time of rap1a industrial innovation in the field of biotechnology, 
it is essential that the European Community respond quickly and effectively 
to the need for protection of human health and the environment and 
strengthening of the common market for these products. Responding to the same 
circumstances, there is a natural temptation for the individual member states 
~ach to·- embark ;:gn the. preparation of domestic legislation. This could 
obviously lead to a proliferation of inconsistent national regulatory 
systems. 
It is clearly incumbent upon the institutions of the European Community to 
anticipate and act to prevent such a situation from arising. 
The following pages describe Community regulatory activities relating to 
biotechnology. In each area are presented : 
- the objectives of the activity and background; 
- the content of current directives, recommendations, etc; 
- the current situation and potential initiatives; 
the committees which provide technical advice to 
these areas. 
the Commission in 
2. REGULATIONS AND COMMUNITY ACTIONS 
This section outlines the current Directives which may be of relevance to the 
regulation of biotechnology in the European Community. 
The sequence of the sections follows the linear logic: from research, to 
production, to marketing, use of products, and finally waste treatment. 
The scope of al'eas selected· for discussion reflects the breadth of potential 
applications of biotechnology. Since the term itself is open to differing 
definitions, and its future technological development and commercialisation 
are not in detail predictable, the scope adopted in this report is fairly 
broad. Thus, for example, Directives are mentioned or described for fields 
which may not currently be the taPget of "biotechnology-based" product or 
prr)cess development, but which might become so. 
2.A. RESEARCH 
The initial creation and propagation of genetically modified organisms 
generally takes place in a research laboratory, and·historically it was with 
this type of activity that regulatory debate on biotechnology first took 
place. 
Council Recommendation concerning the establishment of safety measures 
against the conjectural risks associated with rDNA work <82/472/EEC>. 
At the same period, the Commission services decided to' draft· a Council 
Directive concerning the establishment of safety measures against the 
conjectural risks associated with rDNA work. 
After further widespi~ead debate, and a general reduction in the assessed 
level of possible risks <in the light of experimental results, the absence of 
adverse incidents, and the development of fuller scientific understanding>, 
the Commission in 1980 replaced its draft directive by the recommendation 
which was finally adopted by Council in June 1982 <82/~72/EEC>, concerning 
the registration of rDNA work. 
The same text also formed the basis for the recommendation adopted in October 
1984 by the Council of Europe 
Contents 
The recommendation to the Member States is that they adopt laws, regulations 
and administrative provisions requiring prior notification by laboratories of 
their intention to undertake rDNA work. Notification should be accompanied 
by safety-relevant details of the experimental protocol; a list of protective 
and supervisory measures to be applied; and a description of the training in 
rDNA work of those concerned with the execution, supervision, monitoring or 
safety of the experiment. 
Current situation 
In June 1983, the services of the Commission sent to national experts 
nominated by the delegation of CRM <Committee on Medical and Public Health 
Research of the European Community> a questionnaire designed for allowing an 
appraisal of the state of implementation in the Member States of the 
recommendation by Council concerning the registration of recombinant DNA 
work. The questionnaire also requested from the experts that they expressed 
their opinion on any modification of the recommendation, including its 
abrogation or its replacement by a Council directive, which they would 
consider necessary. 
Synthesis of answers received 
The answers received indicate that: 
- The United Kingdom and Denmark are the only two Member States where a 
system of notification has been rendered compulsory to all laboratories; 
In the Federal Republic of Germany notification is compulsory for 
research work supported by the government. Research not funded by the 
federal government is submitted to a system of voluntary registration; 
Objectives and background 
Following the initial scientifi~ successes of genetic engineering, 
recombining DNA from different organisms to create a novel genome, 
apprehension was expressed by some scientists about potentially serious and 
uncontrollable consequences of the creation and proliferation of new 
organisms. The Asilomar conference in 1975 was followed by voluntary 
adoption of severe constraints on the types of experiments pursued and the 
safety measures to be adopted. These included both physical containment, and 
<through the use of disabled host organisms unlikely to survive outside 
artificial conditions> biological containment. 
In the USA, a detailed regulatory system was imposed on all laboratory rDNA 
work funded by the National Institutes of Health. This was supervised by the 
Recombinant DNA Advisory Committee <'NIH-RAC'>. In the UK, following the 
establishment of a national consultative committee <'GMAG': Genetic 
Manipulation Advisory Group>, an equally strict but more flexible system of 
regulation was imposed. Throughout the other Member States of the Community, 
consultative committees were constituted similarly to GMAG, and 
recommendations usually based on the American or British models were adopted. 
In 1976, the EUI~opean Science Foundation established an expert group, 
including a representative of the Commission, to examine in detail the 
question of the risks of rDNA work, to promote harmonisation of national 
legislation, and to formulate appropriate recommendations. 
2.8. INDUSTRIAL PRODUCTION 
The safety of the industrial use of organisms is secured by providing 
appropriate conditions of containment to prevent release of potentially 
hazardous agent into the outside environment and to protect the product. The 
primary objective in selecting containment is to match an appropriate level 
of physical measures and safety procedures to the conclusions of a risk 
assessment of the biotechnological process involved. 
2.8.1. WORKER PROTECTION 
:-"·.: ,--
Title 
Directive 80/11 07/EEC of 27 November 1980 concerns the protection of 
workers from the risks related to exposure to chemical, physical and 
biological agents at work. 
Objectives 
The Directives sets out two objectives: 
- The elimination of exposure to chemical, physical and biological 
agents and the prevention of risks to workers' health and safety; 
- The protection of workers who are likely to be exposed to these 
agents. 
Contents 
This Directive requires the Member States to take short and longer term 
measures, and it also foresees the adoption by Council of individual 
Directives laying down limit value<s> and other specific requirements 
for named agents. 
In order that the exposure of workers to agents is avoided or kept at as 
low a level as is reasonably practicable, Member States should comply 
with a set of requirements, but in doing so they have to determine 
whether and to what extent each of these requirements is applicable to 
th~ agents concerned. 
- The laboratories involved in recombinant DNA work in Belgium; France, 
Greece, Ireland, and the Netherlands are reported-to comply to a system 
of voluntary registration. 
- With few exceptions, the systems implemented in Belgium, Denmark, the 
Federal Republic of Germany, France, Greece, Ireland, the Netherlands, 
and the United Kingdom take into account all the specifications 
recommended by Council. Ireland, however, adopted a definition of 
recombinant DNA work different from the definition outlined in the 
recommendation; 
- Specific safety regulations, compatible with the terms of the 
recommendation, are now being prepared in Italy; 
One suggest ion <Ire land> was made for the abrogation of the 
recommendation; requests for its replacement by a directive were 
presented by Belgium and Greece. In Greece, however, where existing 
notification procedures are to be complemented by detailed guidelines, 
the view is held that a recommendation implemented by all Member States 
could be considered as adapted to the present situation. The answers 
received from the Netherlands express the view that the recommendation, 
considered as non-adapted, should not be abrogated or modified; it 
should, however, if not implemented by all Member States, be tranformed 
into a directive. No changes are suggested in the other Member States 
(OK, F, FRG, I, UK> where the recommendation is reported to be adapted 
to the current situation. 
Advisory Committees 
The Medical Research Committee advices the Commission on safety aspects of 
laboratory rDNA work. 
The Management and Coordination Advisory Committee <Biotechnology> aav1ses 
the Commission on the execution of its research programmes in biotechnology. 
The DG V paper states that microorganisms can be classified into 
four groups: 
Group 1: An organism that is most unlikely to cause human disease. 
Group 2: An organism that may cause human disease and which might 
be a hazard to ~orkers but is unlikely to spread in the 
community. It rarely produces infection and effective 
prophylaxis or effective treatment are usually available. 
Group 3: An organism that may cause sever-e human disease and 
present a serious hazard to worker's. It may present a 
risk of spread in the community but thePe is usually 
effective prophylaxis or treatment available. 
Group 4: An organism that causes severe human disease and is a 
serious hazard to workers. It may present a high risk of 
spread in the community and there is usually no effective 
prophylaxis or treatment. 
This classification is pr-actically identical to that ppoposed by 
the Safety in Biotechnology working group of the European 
Federation of Biotechnology. 
No particular measures are required for those organisms which are 
non-pathogenic and are classified in Group 1 , but containment 
procedures are required for Groups 2, 3 and 4. A working paper 
has been drafted by the Commission services, setting out defined 
containment levels for each of the three hazard groups, and for 
animal room containment levels relating to work with vertebrates 
deliberately inoculated with organisms in each of the three hazard 
groups. 
b> Monitoring. asses~ment. measurement, prevention 
The Commission's proposal in 1982 for a Council Resolution < COM 
82/690 
final> establishing a second programme of action of the European 
Communi ties on safety and health at work in point 12 was to 
"Establish the principles and criteria for monitoring groups of 
workers likely to be at high risk to their health and safety, in 
particular maintenance and repair teams, workers undertaking 
sub-contract or temporary work, laboratory workers and those 
involved with biotechnology and other new technologies". 
The Council deleted the reference to biotechnology and other new 
technologies. <OJ c 67, 8.3.84>. 
These requirements are: 
- Limitation of use at the place of work; 
- Limitation of the number of workers exposed; 
- Prevention by engineering control; 
• 
- Establishment of limit values and of sampling and measuring 
procedures, and methods for evaluating results; 
- Collective and individual protection measures, 
agents cannot be avoided by the other means, 
measures; 
- Emergency procedures for abnormal exposures; 
- Information for workers, 
- Surveillance of the workers' health. 
Current Situation 
a> Containment 
where exposure to 
as well as hygiene 
A study on the health risKs of workers exposed to chemical and 
biological agents including dangerous pathogens has been carried 
out, under CEC contract, to collect and examine the available data 
with a view to identifying the hazards and drawing up conclusions 
and recommendations concerning them. Following a meeting in July 
1985, DG V prepared a paper relating to the control of pathogenic 
organisms by containment, discussed in February 1986 by a 
specialist working group of the Advisory Committee named below, 
which will consider in May 1986 the recommendations of the group. 
2.8.2. INDUSTRIAL PRODUCTION - CONTROL OF ACCIDENTS 
The Council Directive on the major accident hazards of certain 
industrial activities <821501/EEC>, known as the "Seveso" Directive, 
concerns the protection of the public and the environment from the 
accidental release of harmful material from the industrial use of 
biotechnological processes. 
Objectives 
The Directive was adopted in 1982, in response to a series of major 
industrial accidents in chemical plants in the European Community 
<Flixborough, Seveso>. It set up 2-tier system that requires measures 
to be taken by industrial plant operators and governments to prevent 
major accidents and to limit the consequences of those that do occur. 
Contents 
The Directive imposes general requirements on industrial operators to 
avoid and control the impacts of major industrial accidents arising from 
certain specific activities, including most processing and storage by 
the chemical industry. Then, for a list of 178 dangerous substances, 
the Directive requires the industrial operator to carry out a detailed 
risk assessment and submit a notification to the competent authority of 
the member state setting out risks, controls, and emergency response 
procedures. In the case of an accident, the Directive requiPes member 
states and industrial operators to take further steps to control and 
repair the impacts of the accident and to inform the European Commission 
of what is done . 
.. 
Current Situation 
The Commission services are reviewing the applicability of the Directive 
to industrial processes using microorganisms and considering the need 
for either amending the Directive specifically to include certain 
dangerous organisms or adopting new legislation setting out approriate 
measures to prevent accidents and control their impacts. 
Advisory Committee: 
The Advisory Committee on Safety, Hygiene and Health protection at Work. 
Contents 
The "Sixth Amendment" is intended to ensure that all "new" Chemical 
substances placed on the EC mat,ket after a specified date are tested and 
assessed for their potential risks to people and the environment, - and 
appropriately labelled. 
The manufacturers of new chemical substances must 
carry out a "base set" of tests to identify the potential risks of the 
chemical; 
- Conduct a risk assessment; 
- Adopt appropt,iate labelling according to EC standards; 
- Notify this information to their national competent authority <who 
forwards the dossier to the Commission and thereby to the other member 
state>, and 
Carry out further tests and provide futher information about risks 
according to certain criteria specified in the directive. 
In essence, the directive establishes an information system based on the 
notification dossier which ensures that industries generate the information 
necessary to identify potential risks and that the EC and the member states 
receive the information necessary to monitor potential risks and ensure 
compliance with the directive. 
Current Situation 
Evidently, a different set of information is needed for the evaluation of 
risks from biological processes or living organisms than for non-living 
chemical substances. Rather than attempt to modify the Sixth Amendment to 
the information needs of both chemicals and biotechnology, it may be better 
to apply the approach of the Sixth Amendment - the information system - and 
develop a new Directive aimed at the use of genetically modified and exotic 
organisms. 
Thus, it appears that new legislation may be necessary to establish a 
comparable notification system for the industrial and environmental use of 
genetically modified and exotic organisms. Because no Member State or any 
other country yet has legislation in this field, the Community has here an 
important opportunity to fix the parameters of the regulatory discussion for 
itself and to provide a model for other countries. 
2.C. TESTING AND MARKETING 
There is no doubt of the need to assess the potential impacts on human health 
and the environment from the use of genetically modified organisms in advance 
of production and marketing so that any necessary preventive measures can be 
taken. Evaluation of potential risks is only possible· if the appropriate 
data are generated and made availaHle to regulatory authorities. Clearly, 
this must be primarily the responsibility of the industries which develop the 
new processes and products. 
From this point of view, regulation means setting up a framework for the 
generation of data about the hazards and exposure to biotechnological 
processes and products, risk assessment, and the transmission of this 
information-to government and, to some extent, the public. 
Council Directive amenawg for the sixth time Directive 67/548/EEC on the 
approximation of the laws, regulations and administrative provisions relating 
to the classification, packaging and labelling of dangerous substances 
<79/831/EECl <the so-called "Sixth Amendment" on the testing and notification 
of new chemical substances). 
Objectives and background 
The Directive derives from the growing awareness during the 1970s of the role 
that chemical substances play in damage to human health and ~he environment. 
Only a tiny percentage of the some 55.000 chemicals currently on the world 
market have been extensively tested for their health and environmental 
effects; we have almost no knowledge of their synergistic effects. 
A more comprehensive, preventive approach clearly was needed to supplement 
the restrictions on specific chemicals that were adopted in reaction to clear 
problems. Yet it would be impossible to mandate post hoc testing of all of 
these substances. So the decision was made to focus only on "new 
substances" - those mal"'keted after a specific date - but to require testing 
and a comprehensive, initial risk assessment before sizable quantities of 
these new chemicals could be marketed. At the same time, the Community could 
ensure that the EC market remained open to these substances by creating a 
single, EC notification system, thereby overcoming the restrictions in the 
laws of several Member States which had been adopted beforehand. 
2.0. PRODUCTS AND USES 
• 
Biotechnology's increasing significance is based upon recent and continuing 
rapid advances in understanding of biological processes. This understanding 
has widespread applications for the development: 
Of new processe~ <e.g. for the manufacture of existing or new products 
by biological or biomimetic methods>; 
Of new~ <e.g. in industry, agriculture, health care, environmental 
management; based on the advances in understanding, and employing new or 
existing products>; 
Of new products, 
produced by them, 
including modified organisms and cells, molecules 
and molecules designed to interact with existing or 
modified organisms and cells. 
The novel character, potency, and potential for unintended and harmful 
effects are prima facie reasons for considering whether biotechnology demands 
new regulatory initiatives on the part of the public authorities. 
In this section are considered the regulatory aspects of new products, 
produced by biotechnology, and of new uses, based upon advances in biological 
understanding. 
The section is divided into the following sectoral areas of products and 
uses: 
2.0.1. Pharmaceuticals and veterinary medicines 
2.0.2. Foodstuffs 
2.D.3. Chemical-Based Products 
2.0.4. Agriculture 
2.0.5. Cosmetics 
2.0.6. Product liability 
2 
2.D.1. PHARMACEUTICALS 
The pharmaceuticals sector is currently the sector towards which many of 
the innovations of biotechnology are directed. The novel character of 
some of the classes of product may demand corresponding regulatory 
. . . . 1 1n1t1at1ves . 
Objective 
The results of twenty years of harmonization of pharmaceutical 
regulations in Europe, governing both human and veterinary medicines, 
now comprise seven,. basic Directives, one Council Recommendation and 
various other texts2 . These rules cover most medicines, but exclude 
immunological, blood and radioactive products and homeopathy. 
Five important consequences have resulted for the movement of medicines 
within the Community: 
a> The criteria of the quality, safety and efficacy of drugs have 
been progre~sively harmonized in Europe, as have certain aspects 
of procedures for marketing authorization <time-limits, giving of 
reasons, publication> or for manufacture <quality control, 
inspections>; 
This sub-section is based upon a fuller paper, "Biotechnology and Rules 
Governing Pharmaceuticals in the European Community", prepared by the 
Commission services, published in January 1986, and available on request 
<in English or French> from DG III-A-3. 
Council Directive 65/65/EEC, OJ N° 22, 9.2.1965 
Council Directive 75/318/EEC, OJ N° L1~7,9 6.1975 
Council Directive 75/319/EEC, OJ N° L1~7.9.6.1975 
Council Directive 78/25/EEC, OJ N° L11, 1~.1.1978 
Council Directive 81/851/EEC, OJ N° L317,6.11.1981 
Council Directive 81/852/EEC, OJ N° L317,6.11.1981 
Council Directive 83/570/EEC, OJ N° L332,28.11.1983 
Council Recommendation 83/571/EEC, OJ N° L332, 28.11.1983 
A booklet containing these may be bought from the Office for Official 
Publications of the European Communities, L-2985 Luxembourg - Catalogue N° 
CB-41-8~-515 
The relatively voluminous content of these propos~ls·may be summarized 
as follows: 
a> Pl'iOl' Community consultation on high technology/biotechnology 
medicines <1st proposal> 
It is proposed that competent authorities be obliged to consult 
through the Committee for Proprietary Medicinal Products or the 
Committee for Veterinary Medicinal Products, before they decide to 
authorize, refuse of withdraw any high technology medicine. The 
firm concerned is a direct party to this procedure which runs 
strictly parallel to the national examination procedure should be 
initiated systematically in the case of biotechnology, which the 
Community considers to be a priority, or at the request of the 
firms concerned, in the case of other high technology medicaments. 
Furthermore, the Member States would be obliged to notify the 
Commission of any draft national regulations affecting the 
manufacture, marketing or use of biotechnological medicines, so as 
to give the Commission the opportunity to adopt regulations for 
the entire EC, thus preventing futher segmentation of the common 
market. This control over the proliferation of national 
regulations would be parallel to the information procedure on 
technical standards and regulations laid down by Directive 
83/189/EEC. 
bJ Updating of reguirements in respect of drug testing and 
simplification of the procedures for their subseguent review 
<2nd, 3rd and 4th proposals> 
The present programme on the adoption, or amendment, of standards 
and protocols for drug testing requires the unanimous agreement of 
the Member States. The current delays of four to six years may 
well be lenghened with the recent enlargement of the Community. A 
veto by a national delegation can, in fact, prevent both the 
adoption of new provisions aimed at achieving increased protection 
of public health, and the removal of absolete requirements <e.g. 
in toxicology: reduction of the number of animals tested, gradual 
introduction of in vitro tests>. The Commission is therefore 
proposing to the Member States that a simplified procedure be 
adopted for adapting Directives 75/318/EEC and 81/852/EEC to 
technical progress, a procedure which safeguards public health 
because it involves the agreement of a very large majority of the 
delegations. 
At the same time, compliance with the principles of good 
laboratory practice <GLPs> will be explicitly required in the 
performance of safety tests. 
·"7 
b> The analytical and pharmacotoxicological tests ahd clinical trials 
with drugs, performed in accordance with the Community rules, need 
no longer be repeated within the Community; 
c > The tests of manufactuPing batches carried out in the produeing 
country are accepted by the other Member States; 
d> The general requiPements concePning labelling OP package inserts 
have been haPmonized; 
e> A common list of colouring matters permitted for use in medicines 
has been adopted. 
The five Commission propoc;als to promote high technology and 
biotechnology medicines 
In 1983, the Commission requested the European pharmaceutical industry 
to pinpoint the chief obstacles to the development of biotechnology in 
this area. The Peplies were given in FebPuapy 1984 by EFPIA in a major 
Pepopt entitled "The EuPopean Pharmaceutical Industry and the 
Development of Biotechnology"~ 
Simultaneously, the Commission consulted the vaPious committees on which 
the competent national authorities were Pepresented. 
It was agPeed that the Community pharmaceutical rules ppovide a 
genePally valid basis fop the assessment of drugs derived from 
biotechnology, although some adaptations were desirable. Furthermore, 
it was necessary to avoid freezing scientific progress in this sector by 
the introduction of new and massive bodies of legislation which 
concentrated exclusively on biotechnology. Other advanced technologies 
also offer new prospects for pharmaceutical research Ce.g., new delivery 
systems, purification under conditions of microgravity, etc.>. 
Contents 
In october 1984, the Commission submitted to the Counci 1 a report 
together with five proposals for legislative measures for high 
technology mea1c1nal products, particularly those derived from 
biotechnology. CCOMC84)437 and OJ N° C293, 5.11.84>. The first proposal 
refers specifically to "high technology and biotechnology" dPugs, 
whereas the other four measures cover all medicines, but are considered 
to be especially useful for these "high technology" drugs. 
J EFPIA, 250 Avenue Louise, Bte 92, B-1050 Brussels 
On 18 and 19 March 1985, the Commission arranged an i~portant meeting on 
the theme of "Pharmacy/Biotechnology" concerning t~e joint actions to be 
implemented under existing Community pharmaceutical rules for medicines 
derived from biotechnology. The participants at the meeting agreed that 
any application concerning a biotechnological medicine cound be referred 
to the Committee for Proprietary Medicinal Products CCPMP> or- the 
Committee for Veterinary Medicinal Products CCVMP> for op1mon, upon the 
request of the company concerned, even before -an initial national 
decision has been taken. • 
More recently, the Commission set up a Working Party on Biological 
products in collaboration with the CPMP and the CVMP, which will draft 
flexible guidelines for assessing medicaments derived from 
biotechnology, on the pattern of the documents entitled "Points to 
consider" published by the Food and Drug Administration. 
During the Pha:;:~mc:scy/Biotechnology meeting, it was considered advisable 
to extend the Community pharmaceutical rules to biological medicines 
which are not yet covered by them, since biotechnology should permit the 
development of improved vaccines and new vaccines in many spheres in 
which prevention is still difficult or non-existent. The other 
immunological products and substitutes for blood products which could 
show rapid expansion will also be taken account of this work. 
In response, the Commission intends to cover these aspects with new 
proposals for legislation on 1987. 
The Commission is also paying close attention to the regulatory position 
of in vitro diagnostic agents, which are likely to make new progress 
thanks to biotechnology. The Community might have to step in, if 
national measures lead to further compartmentalization of the markets. 
2.0.2. FOODSTUFFS 
The increased understanding of human nutrition, the continuing analysis 
of consumers' changing preferences, requirements and constraints, and 
the continuing advances in the science and technology relevant to the 
processing and transformation of the materials used as foodstuffs -
mainly of biological or1g1n all combine to create continuing 
innovation in the food and drink industry. Biotechnology offers a range 
of new product possibilities in this sector. 
The protection of consumer safety, and integrity in product description 
and labelling, demand regulatory procedures which are adapted or 
developed as necessary to the challenges of continuing innovation. 
c> Towards protection of pharmaceutical reseal'ch and development over 
a minimum period of ten years 
<5th proposal> 
In all of the industrialized countries, companies have to -test 
their new medicines over many years and then await a detailed 
examination of their licensing applications before being able to 
market their products. Efut firms that wish to market a copy aof a 
drug, especially a generic product, only have to demonstrate the 
quality of the copy and, if necessary, its bioequivalence in 
regard to the original product. Repetition, in animals or humans, 
of tests whose results are already known is not acceptable from 
the ethical point of view. 
However, it is not fair if a copier can quickly place a drug on 
the market without contributing towards the heavy costs of all the 
experiments which led to the medicinal innovation. 
The protection normally afforded by patent law is inadequate in 
this case, since the maximum period of protection of 20 years, is, 
in fact, reduced to less than 10 years when the duration of the 
tests and the licensing ?rocedure is taken into account. 
Consequently, the solution suggested by the Commission chiefly 
consists of obliging the copier: 
Either to try to obtain the or1gmating firm's consent to 
allow reference to be made to the original tests ( for a 
financial consideration>; 
- Or to wait for 10 years from the date of the marketing 
authorization of the original medicine before being able to 
submit a dossier in simplified form retaining mainly the 
quality of the copy. 
Current Situation 
On 27 March 1985, the Economic and Social Committee expressed a very 
favourable opinion on these five proposals. The European Parliament 
similarly gave a favourable view on 16 January 1986. 
The Council is expected to approve this series of five 
1986. 
measures in 
Examples of "horizontal" measures include Directives on · labelling, 
additives, and methods of analysis for the monitoring of foodstuffs. 
"Vertical" measures include Directives on sugar, jams, cocoa and 
chocolate. 
Current Situation 
A first meeting with Member States experts has been held to consider the 
need to adapt some existing Directives to take account of any possible 
hazards which might be presented by the incorporation of 
biotechnologically-derived ingredients or additives in foodstuffs. A 
preliminary reaction would indicate that no adaptations would appear to 
be necessary in the legal text, but some protocols of assessment would 
need to be modifi2ci. The question is being left under review on a 
case-by-case basis. 
Committees 
Scientific Committee for food 
Commission decision of 16 April 1974. 
Objectives and background 
The Commission has over the past twenty years introduced, and the 
Council has approved, a large number of measures aimed at eliminating 
technical obstacles to trade in foodstuffs, as in other industrial 
products, ar1s1ng from differences between the legislative, regulatory 
and administrative measures applied in the Member St~tes4 . 
. 
The basic general Council Resolutions are as follows: 
1. That of 28 May 1969: 
- Establisrdng a programme to eliminate technical obstacles to 
trade in general; 
- The same, with particular reference to foodstuffs; 
- Concerning mutual recognition of controls; 
- Concerning the adapta~ion of directives to technical progress. 
2. That of 17 December 1973, concerning industrial policy <which 
contained a calendar for the elimination of obstacles to trade in 
both industrial goods and foodstuffs>. 
Mention should also be made of the recent document: "Completion of 
the Internal Market: Community Legislation on Foodstuffs", a 
communication from the Commission to the Council: COMC85>603 Final 
of08.11.85. 
Content of current measures 
These may be grouped into two classes: "horizontal" measures, app1y1ng 
across many categories and "vertical" specific to a particular 
foodstuff. They include Council Directives, Commission Directives and 
other Community instruments. Several subjects are under discussion in 
the Council. 
4 A comprehensive list of Community legislation and related documentation up 
to 1 June 1982 is given in Documentation Bulletin 86 of the Commission, 
"L' Elimination des Entraves Techniques aux Echanges des Denrees 
Alimentaires". A separate 7-page note updates this to 1 March 1985. A new 
edition <1986) will be published shortly. 
2.0.4. AGRICULTURE 
The biological basis of all agricultural activity implies correspona1ng 
widespread potential for biotechnological innovation, wherever a deeper 
understanding of biological processes and the development of suit.:~bly 
designed bio-active products allows for more cost-effective production 
methods. 
• 
Not included here are fertili~ers <grouped with chemicals, see preceding 
section 2.D.3. > and veTerinary medicines <grouped with pharmaceuticals, 
see section 2.0.1 .>. 
Objectives 
The general aim of the several Directives referred to below is to 
establish a common European system of regulation for the products 
concerned, thereby opening the European market to all such products as 
meet the requirements of these Directives, and to provide harmonised 
high standards for the protection of the heal "Ch and interests of the 
consumers, the health of agricultural animals, and the environment. 
The regulations established or proposea 1n the field of harmonisation of 
legislation concerning products used for veterinary purposes <excluding 
medicaments>, in animal nutrition or for plant protection have as their 
aim the admission only of products of proven efficacy, and whose use, in 
the conditions defined, carries no dangers for human or animal health, 
or for the environm~nt. 
Given the wide range of objectives pursued by the use of the products in 
question, the regulations established or proposed in this field are 
specific in the sense that they always relate to groups of products 
linked by a common objective. One may cite by way of example: the 
Directives or proposed Directives concerning additives to animal 
f eedstuffs, substances of thyrostat ic, oestrogenic, androgenic or 
gestagenic effect, medicated f eedstuffs, EEC type approval of plant 
protection products, etc. 
The regulations in question are therefore established is such a way that 
all the factors involved by the circulation or use of these products 
<both in terms of efficacy and in terms of risk to human or animal 
health, or to the environment> are taken into consideration in the 
context of the objectives pursued, whatever their source or the 
production technique. 
It follows from this situation that if "horizontal" measures had to be 
taken for the products of biotechnology, they should be limited, so far 
as concerns products used for veterinary purposes <excluding 
medicaments>, in animal nutrition and for plant protection, to 
dispositions concerning research and production. 
2.D.3 CHEMICAL-BASED PRODUCTS 
Biotechnology can sometimes provide an alternative and more economic 
method for the production of chemical products. Molecules of biological 
origin may themselves be classed as chemical products; whether this 
might be extended to include complex assemblies of diverse molecules 
such as constitute plasrnids, viruses or whole viable organisms, remains 
to be studied. 
Objectives 
-The. aim of Community regulation of chemical products is the provlslon of 
a harmonised com~o~ market for trade in all chemical products meeting 
the requirements of the corresponding Directives, with a high standard 
of safety for the protection of product users, the general public and 
the environment. 
Content of current measures 
The basic Directive .67/548/EEC concerning the classification, packaging 
and labelling of dangerous substances has been discussed under section 
2C, Tes~ing and Marketing. 
The characteristics of certain chemical substances and preparations have 
led to specific Directives concerning the products in the specific areas 
mentioned in the following lists: 
Current Situation 
The impact of biotechnologically-derived products and products 
components on the substance of the existing Directives is kept under 
review. 
Content 
This Directive covers all products meeting the requirements for 
admission as additives in animal nutrition. These include natural 
products, synthetic products and products of bacterial fermentat-ion. 
The requirements concerned are established by the Directive and 
specified in the "Guidelines". Other article~ govern labelling 
provisions. • 
Annex lists additives permitted throughout the Community, Annex 2 
those whose use may be permitted nationally for a limited period. 
Current situation 
The gu10ennes are currently being updated by the Scientific Committee 
on Animal Nutrition. In particular, it is envisaged that dispositions 
will be introduced concerning the declaration of any genetic 
modification undergone by the microorganisms used for the production of 
additives, and the possible tests to which such products should be 
submitted. 
The Directive on certain <protein or related> products 
Objectives 
The objective of this Directive are to ensure that certain novel 
substances in animal nutrition have nutritional value because they 
supply nitrogen or protein; in normal use, have no unfavourable 
influence on human or animal health or the environment; and no effect 
prejudicial to the consumer through altering the characteristics of the 
animal products. 
Content 
This Directive covers biotechnology products meeting the requirements 
for admission as feedstuffs or feedstuff constituents for animals. 
These requirements are established by the Directive and specified in the 
Guidelines which are the object of Council Directive 83/228/EEC. The 
case of microorganisms subjected to genetic manipulations is included. 
Regarding the selection of plants and animals modified · by genetic 
engineering, their utilisation does not present "any problems greater 
than those resulting from classical methods of selection. 
Content of Current Measures 
In general, the provisions concern: 
- The character of the product; 
- Criteria for admission and/or examination; 
- Control of compliance with the rules; 
- Exception provisions; 
- Procedural prov1s1ons. Under certain of these, management powers 
have been delegated by Council to the Commission, to act by means 
of regulatory committees <called standing committees>on which the 
Member States are represented. 
Animal feedstuff~ 
Council Directive concerning additives in animal feedstuffs <70/524/EEC> 
Council Directive concerning certain products used in animal feedstuffs 
(82/471/EEC> 
The Directive on additives 
Objectives 
The objectives of this Directive are to ensure that all additives used 
have some beneficial effect; no harmful effects on animal or human 
health, nor prejudicial alteration of the animal product 
characteristics; that they are controllable in the fedstuffs; have no 
prophylactic or therapeutic effects at the levels used; and do not have 
to be reserved for medical or veterinary use for serious reasons 
concerning human or animal health <e.g. spread of antibiotic resistance 
in infective organisms>. 
Vegetable seed and plant varieties 
Counci 1 Directives concerning the common catalogue of varieties of 
agricultural plant species C70i457/EEC>; and the marketing of vegetable 
seed <70/458/EEC>. 
Objective and content 
These Directives concern the aaDnssion to the common catalogues of 
varieties whose seeds or plants may be marketed in the EEC. A variety 
should be distinct, stable, and sufficiently homogeneous, harmless to 
other cultivated species. The origin of the variation may be artificial 
or natural. A Standing Committee elaborates the criteria and methods of 
examination. 
Council Directive concern1ng pedigree breeding cattleC77/504/EEC>. 
Objective and content 
This Directive authorises free trade within the Community of pedigree 
breea1ng cattle, their sperm and fertilised ova, permits the 
establishment of genealogical records, and recognises the organisations 
responsible for them. 
With the help of the standing zootechnical committee, there are 
established methods for evaluating genetic value and performance of 
cattle, recognition criteria for the breeders' organisations, criteria 
for record-keeping and information to be entered on genealogical 
certificates. 
Council Directive 
having hormonal 
< 81 ./602/EEC). 
concerning 
effect and 
the prohibition of 
substances having 
certain substances 
thyrostatic effect 
Plant protection products 
Council Directive concerning the prohibition of the-marketing and use of 
phytopharmaceutical products • containing certain active substances 
<79/117/EEC> 
Objective 
The objective of this Directive is to prohibit the use of products -
even where appropriate for the end in view - if they present or risk 
presenting effects harmful to human or animal health, or unacceptable 
unfavourable effects on the environmant. 
Content 
This Directive already covers all microorganisms and viruses having an 
anti-parasite effect. Moreover, the Directive allows for the 
prohibition, if need be, of a phytopharmaceutical product resulting from 
biotechnology, which present unacceptable risks for public health or the 
envi!~onment. 
The stana1ng phytosanitary committee is consulted regarding modification 
of the list of prohibited substances and for authorising the temporary 
use of a product. The annex lists forbidden substances and describes 
authorised uses. There are two groups of substances: A, mercuric 
compounds; B, persistent organochlorine compounds. 
Current situation 
The Commission has prepared a draft directive concerning the type 
approval of phytopharmaceutical products which could circulate freely in 
the Community COJ 212 of 9.9.1976, P.3.>. 
This proposal envisages the establishment, once it is agreed, of 
"Guidelines" for the control of the general requirements of the 
Directive. Draft "Guidelines" have been elaborated, not only for 
chemical products but also for biological pesticides. 
In principle, these "Guidelines" should also be applicable for the 
evaluation of biological pesticides resulting from genetic manipulation; 
this question is currently under examination by the Scientific Committee 
on Pesticides. 
2.D.5 COSMETICS 
Cosmetics containing ingredients that have been produced by 
biotechnological agents are already on the market in one country, at 
least. This could be major area of rapid growth 1n products. 
Council Directive on the approximation of the laws of the Member States 
relating to cosmetic products <76/768/EEC>. 
Objectives 
The Directive intends both to establish an European system of cosmetics 
regulation, thereby opening the European market to all cosmetics that 
meet the requirements of the directive, and to provide harmonised, high 
standards for the protection of the users of cosmetics. 
Contenr:s 
The Directive regulates the contents, labelling and packaging of 
cosmetics. It fo1•bids the use of certain substances in cosmetics, 
regulates the use of certain other substances, and permits the temporary 
use of certain substances that are already in use in one or more Member 
States. It also contains a "positive list" of substances that are 
definitively permitted. 
Cosmetics that comply with the Directive may be freely traded in the 
European Community. Member states may permit the use of non-EC-approved 
substances for up to 3 years. A committee is established to decide what 
substances should be regulated, and to adapt the Directive to technical 
progress. 
The Commission is aided by a Scientific Advisory Committee for 
Cosmetics. 
Current Situation 
The Directive will be reviewed for its applicability to biotechnological 
products. 
Objective and content 
Under Article 2, the Member States ensure the prohibition <except as 
under Articles 4 and 5>, of 
a> The administration to an agricultural animal; 
substances having thyrostatic effect and of 
oestrogenic, androgenic or gestogenic effect; 
by any means, of 
substances having 
b> The mari<eting or slaughter of animals to which such substances 
have been administrated; 
c> The marketing of the meat of such animals referred to under b>; 
d> The transformation of meat as referred to under c> and of products 
based upon or with such meats. 
Under Article 3, the Member States forbid the marketing of stilbenes 
and their derivatives, salts and esters, as well as thyrostatics, with a 
view to their adminsitration to animals of any species. 
Article 4 allows for the use in therapeutic treatment of the products 
referred to in Article 2. 
Articles 5 envisages a Council Decision at the earliest possible date 
<see below, Council Directive of 31.12.85> concerning the administration 
to agricultural animals of products for the purpose of fattering. 
Council Directive prohibiting the use in livestock farming of certain 
substances having a hormonal action <31.12.1985>. 
Objective and content 
This Directive was established as foreseen in Article 5 of Directive 
81/602/EEC <see above>. Other than for therapeutic purposes it 
maintains the ban established by Article 2 of that Directive. 
2.0.6 PRODUCT LIABILITY 
The recent adoption of Community legislation on product liability has 
great implications for the producers of new biotechnology products. 
Council Directive on the approximation of the laws, regulations and 
administrative provisions of the Member States concerning liability for 
defective products <85/374/EEC> 
Objective 
The Directive was adopted last year after 9 years of discussion in the 
Council. It imposes strict liability on producers of defective products, 
for the protection of consumers from defective moveable goods. 
Contents 
It declares that producers and importers shall be jointly and severally 
liable for damage caused by defective products. A product is defective 
when it does not provide the safety which a person is entitled to 
expect. Primary agricultural products and game are excluded from the 
definition of "products", although the Member States are permitted to 
overrule this exception. 
The producer shall not be liable if is proved that the state of 
scientific and technical knowledge at the time when the product was put 
into circulation was not such as to enable the existence of the defect 
be discovered, but the impact of this clause on consumer protection and 
the functioning of the common market must be reviewed by the Commission 
in 10 years. 
The Directive must be implemented by the Member States by mid-1988. 
Current Situation 
Since mid-1988 is the deadline for 
Directive, there is ample time to 
biotechnological products. 
formal implementation of the 
consider its applicability to 
2.E WASTE MANAGEMENT 
Waste management 1s an issue that affects 
Industrial processes using biological 
. 
agents Cindustrial and 
agricultural wastes>; 
-Products Cindustrial and municipal wastes>, and 
- Waste treatment facilities Csewage plants, 
facilities>. 
toxic waste treatment 
Council Directive on toxic ana aangerous waste C78/319/EEC> 
Council Directive on the supervision and control within the EEC of the 
transfrontier shipment of hazardous waste C84/631/EEC>. 
2.E.1 The Dirertive on toxic and dangerous waste 
Objectives 
The Directive was adopted after an earlier directive laid down a broad 
framework of control for waste management generally, including toxic 
waste. It responded to legislation that had been adopted in several 
member states, and provided a common approach procedures, and the basis 
of a system of information exchange about toxic witste management by the 
member states. 
Contents 
The Directive declares that toxic and dangerous waste may be stored, 
treated or deposited only by authorised undertakings. It provides for 
toxic waste management planning and permit systems and defines "toxic 
and dangerous waste" by means of an annexed list of substances. In 
particular, the directive lays down general requirements for the 
appointment of competent authorities to implement the directive, permit 
procedures for their management, recordkeeping, labelling of transport, 
inspection powers, separation and packaging, the allocation of costs, 
and a three-yearly situation reports by the member states to the 
European Commission. 
.. 
• 
• 
Current Situation 
The Commission has begun a review of the applicability of the Directive 
to wastes arising from industrial biotechnological processes. 
2.£.2. The Directive on transf~ontier shipment of hazardous wastes 
Obiective and background 
The Directive was adopted in 1984, soon after the a1sappearanc:e and 
rediscovery of a number of drums of contaminated earth from the region 
around the chemical plant in Seveso, Italy, where an industrial process 
accident caused the emission of clouds of dioxin to the surrounding 
area. It partially applies the OECD Council recommendation on a 
notification system for the international transport of hazardous wastes. 
Contents 
The Directive lays down a notification system by means of a consignment 
note for the transport of hazardous wastes from one EC member state to 
another or to a country outside the EC. Hazardous wastes include those 
defined by the directive, toxic and dangerous wastes <with certain 
exceptions> and PCBs. 
Wastes must be properly packaged and labelled for transport. Every 2 
years, the member states must submit a report to the Commission on the 
implementation of th~-directive. 
Current Situation 
The Directive must be reviewed in terms of its applicability to wastes 
from biotechnological industrial processes or products and in relation 
to the 1978 directive on toxic and dangerous wastes . 
2.£.3 Other issues 
Research is needed on the potential risks to human health and the 
environment from biotechnological consumer products that could enter the 
urban waste stream, and on the implication of the use of microorganisms 
for waste treatment, such as in sewage processing, the detoxification of 
PCBs. etc. 
• 
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